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Abstract
Purpose Little is known about the current role of the gen-
eral practitioner (GP) in breast cancer follow-up care. This
study explores primary healthcare use in the period after
completion of primary breast cancer treatment.
Methods A total of 336 women with a history of early-stage
breast cancer treated with curative intent were identified in
the primary care database of the Registration Network Gro-
ningen (RNG) (1998–2007) and matched with a reference
population of 983 women without breast cancer on birth
year and GP.
Results Over the entire follow-up period (starting 1 year
post-diagnosis), the median numbers of face-to-face con-
tacts, drug prescriptions, and referrals in the patient group
were significantly higher than those in the reference group:
4.0 vs. 3.2/year, 12.3 vs. 8.4/year, and 0.4 vs. 0.3/year,
Mann–Whitney (M–W) test p<0.001 for all differences.
At least one annual face-to-face contact was observed for
96.7 % of patients and 92.9 % of women from the reference
population (Chi-square test p00.011). More patients than
women from the reference population had face-to-face
contacts for reasons related to breast cancer or were
prescribed hormone antagonists and aromatase inhibitors
to treat breast cancer. The main predictor of higher rates
of face-to-face contacts and drug prescriptions was a higher
age at diagnosis.
Conclusions This study shows increased primary healthcare
utilisation among women with a history of breast cancer,
especially among the elderly. When follow-up is transferred
to the primary care setting, new responsibilities of GPs
might be incorporated into existing primary healthcare
delivery.
Keywords Breast cancer . Healthcare utilisation . General
practice . Follow-up care . Primary care database
Introduction
Breast cancer is the most common malignancy and the
leading cause of cancer-related death in women worldwide,
accounting for 23 % of new cancer cases and 14 % of cancer
deaths in 2008 [1]. Survival of breast cancer patients has
increased in many countries as a result of early detection
through mammography and improved treatment [1]. In The
Netherlands, it is expected that further improvements in
cancer screening and treatment, together with the ageing of
the population, will lead to an increase in the prevalence of
cancer survivors. In the coming years, this growing group of
survivors will impose a burden on the Dutch healthcare
system by their demand for cancer surveillance after com-
pletion of primary treatment and general medical care for
co-morbid conditions [2]. This highlights the need for an
effective resource allocation between primary care and hos-
pital care in the future, and possible substitution of routine
cancer follow-up to the general practitioner (GP) [2]. How-
ever, transfer of breast cancer follow-up to the primary care
setting has to be accepted by all parties involved. While the
majority of GPs and other primary care physicians (PCPs)
are willing to accept responsibility for follow-up [3–5], most
patients prefer this to be cared for by specialists [6–9].
Furthermore, patients [10–12] and oncologists [3, 13, 14],
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as well as PCPs [14], have concerns about the amount of
knowledge and skills, and time involved for PCPs to pro-
vide adequate follow-up care.
It is important to know to what extent GPs are already
involved in breast cancer follow-up care. Two studies using
general practice case records, cancer registry data, and
health insurance data showed that contact rates with PCPs
increased during the second and third years after breast
cancer diagnosis when compared to the pre-diagnostic peri-
od [15, 16]. Unfortunately, contact rates of women with a
history of breast cancer were not compared with those of
women without breast cancer. In three cross-sectional sur-
veys, contact with the GP did not differ between breast
cancer survivors 5 years or more after diagnosis and age-
matched controls, or compared with women from the gen-
eral population [17–19]. However, these studies do not
elucidate why patients with a history of breast cancer con-
sult their PCP. Therefore, the present study explores the
reasons for primary healthcare use among women with a
history of breast cancer compared with women without
breast cancer and investigates patient characteristics associ-
ated with this healthcare use in the period after completion
of primary breast cancer treatment.
Patients and methods
Participants and data collection
An analysis of healthcare use (1998–2007) was performed
using the primary care database of the Registration Network
Groningen (RNG). The process of identification of patients
in this database and the collection of additional information
in participating general practices has recently been pub-
lished [20]. Confirmation of breast cancer in history was
obtained for 400 patients. Of these patients, 339 with a
history of early-stage breast cancer and treated with curative
intent were included in the matching process. The remaining
61 patients were excluded for several reasons (Fig. 1). Eli-
gible patients were individually matched to three women
from a reference population without breast cancer on birth
year (±1 year) and GP. Women from the reference group
were eligible if they were registered with the same GP as the
corresponding patients at the matching date. Three patients
could not be matched to at least one woman from the
reference population; these three patients were excluded.
Finally 336 patients and 983 women from the reference
group were available for data analysis.
Patients and women from the reference population were
observed for the entire follow-up period, defined as the
period starting 1 year post-diagnosis, as most patients would
have completed their primary treatment in the first year
since diagnosis. Furthermore, patients and women from
the reference group were observed for the first 5 years of
the follow-up period, when enlisted with their GP in these
years. As in our previous analysis [20], data collected by the
RNG between 1998 and 2007 were entered into an anony-
mous database. Extracted were: patient contacts recorded by
participating GPs using the International Classification of
Primary Care (ICPC) version 1 [21], prescribed medication
automatically classified according to the Anatomical Ther-
apeutical Chemical (ATC) classification, and referrals by
specialty [22].
Data analysis
Annual healthcare utilisation rates in general practice were
calculated by dividing the number of face-to-face contacts,
drug prescriptions, and referrals in the entire follow-up
period (starting 1 year post-diagnosis) by the observation
time in this period. Face-to-face contacts included consulta-
tions in general practice and home visits carried out by GPs
and other general practice workers [20]. Observation time
was calculated as time since matching date until the end-
points (e.g., breast cancer recurrence, death, and departure)
(Table 1). Frequencies of women with at least one annual
face-to-face contact, drug prescription, and referral during
the entire follow-up period were also determined. To exam-
ine reasons for primary healthcare use, frequencies of wom-
en with any face-to-face contact by an ICPC chapter or an
ATC chapter and any referral by specialty per year were
calculated. Furthermore, subgroups were identified based on
Confirmation of breast cancer in history 
(n=400) 
Excluded from matching (n=61): 
• Moved into nursing home before diagnosis (n=1) 
• Distant metastasis at diagnosis (n=11) 
• Recurrent breast cancer: 
- Before the start of study (n=15) 
- Before entry in general practice (n=7) 
- In the year after diagnosis (n=1) 
• End of study before entry in general practice (n=1) 
• End of study in the year since diagnosis (n=20) 
• Moved/other general practitioner in the year since 
diagnosis (n=4) 
• Died in the year since diagnosis (n=1) 
Excluded from data analysis (n=3): 
• Could not be matched to at least one woman from the 
reference population (n=3) 
Diagnosed with breast cancer before 2007 
and included in matching (n=339) 
Included in data analysis (n=336) 
Fig. 1 Flow diagram of the inclusion of patients with a history of
early-stage breast cancer (≥1 year post-diagnosis)
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three-digit ICPC codes and three- to seven-digit ATC codes.
During the follow-up period, 199 face-to-face contacts
(3.1 %) among patients and 525 face-to-face contacts
(2.4 %) among women from the reference group could not
be linked to any ICPC code. In addition, 48 (5.4 %) and 85
(3.0 %) referrals, respectively, were classified as ‘unknown
specialty referral’ or ‘other specialty referral’.
Primary healthcare use in the first 5 years of the follow-
up period was assessed by calculating frequencies of women
with at least one annual face-to-face contact, drug prescrip-
tion, and referral in this period. Based on the results of a
previous study [23], primary healthcare use for psycholog-
ical reasons and endocrine therapy-related reasons was also
assessed. Due to small numbers, ICPC chapters and ATC
chapters were analysed instead of subgroups. To analyse
differences in characteristics, rates, and frequencies between
patients and women from the reference population, non-
parametric tests were used, including the Chi-square (χ2)
test and the Mann–Whitney (M–W) test. A p value of ≤0.05
was considered to be statistically significant. Furthermore,
logistic regression analysis was used to evaluate which
patient characteristics were associated with rates of face-
to-face contacts and drug prescriptions in the entire follow-
up period.
Results
Table 1 presents descriptive characteristics of patients with a
history of breast cancer (n0336) and women from the
reference population (n0983). Median age at diagnosis
among patients was 54.9 (range 23.0–96.0) years. T stage
and N stage were known for 277 patients (82.4 %) and 304
patients (90.5 %), respectively. Regional lymph node in-
volvement was found in 198 patients (65.1 %). Almost
60 % of patients underwent mastectomy (n0186), while
44 % received systemic treatment (n0139). Time since
diagnosis until the matching date ranged from 1.0 to
36.4 years among patients. Median observation time during
the entire follow-up period (starting 1 year post-diagnosis)
was significantly shorter for patients than for women from
the reference group (3.8 vs. 5.2, M–W test p<0.001). This is
mainly due to the fact that recurrent breast cancer was taken
as an endpoint in 53 patients (15.8 %).
Over the follow-up period, the median numbers of face-
to-face contacts (4.0 vs. 3.2/year), drug prescriptions (12.3
vs. 8.4/year), and referrals (0.4 vs. 0.3/year) in the patient
group were significantly higher than those in the reference
group (M–W test p<0.001 for all differences) (Table 2). At
least one annual face-to-face contact was observed for
96.7 % of patients and 92.9 % of women from the reference
population (χ2 test p00.011). More than six face-to-face
contacts per year were found in 31.0 % of patients and
Table 1 Characteristics of women with a history of breast cancer (n0
336) and women from the reference population (Ref.; n0983)
Patients Ref. p value
Age at diagnosis (years) 0.829c
Median (range) 54.9 (23.0–96.0) 54.8 (21.0–94.8)
Categories, n (%) 116 (34.5) 348 (35.4)
≤50.0 120 (35.7) 353 (35.9)
50.1–65.0 100 (29.8) 282 (28.7)
>65.0




















Systemic treatment, n (%)
None 177 (56.0)
Chemotherapy 38 (12.0)





Source of matching date, n (%)b
1 year since diagnosis
of patient
178 (53.0)
Start study (01/01/1998) 113 (33.6)











3.8 (0.1–10.0) 5.2 (0.0–10.0) <0.001c
Endpoints during
observation, n (%)
Recurrent breast cancer 53 (15.8)
Departure 39 (11.6) 126 (12.8)
Death 40 (11.9) 115 (11.7)
Other 4 (1.2) 22 (2.2)
a Including patients treated with lumpectomy followed by mastectomy
b ≥ 1 year post-diagnosis
cMann–Whitney test
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22.9 % of women in the reference group. Significantly more
patients than women from the reference population had any
face-to-face contact for reasons related to the female genital
system in total (48.2 vs. 38.8 %, χ2 test p00.002) (Table 3).
When this ICPC chapter was divided by subgroups,
significant differences were found for breast cancer (19.6 vs.
0.0 %, χ2 test p<0.001) but not for breast symptoms and
vulvar/vaginal symptoms/diagnoses (data not shown). Fewer
patients had any contact for ear problems (29.2 vs. 36.2 %,
χ2 test p00.023), including excessive ear wax (15.8 vs.
21.1 %, χ2 test p00.036). Significantly more patients than
women from the reference population were prescribed anti-
neoplastic/immuno-modulating agents (25.6 vs. 1.6 %, χ2
test p<0.001), including hormone antagonists (tamoxifen)
and aromatase inhibitors (23.2 vs. 0.1 %, χ2 test p<0.001).
Fewer patients were prescribed drugs for conditions
concerning the genitourinary system in total (16.7 vs.
24.7 %, χ2 test p00.002). When this ICPC chapter was
divided by subgroups, significant differences were observed
for non-breast cancer-related sex hormones (6.5 vs. 19.4,
χ2 test p<0.001). Also, fewer patients than women from
the reference population were prescribed drugs for condi-
tions concerning the sensory organs (26.2 vs. 33.9 %, χ2
test p00.009), including ophthalmological preparations
(19.9 vs. 28.4, χ2 test p00.002). No significant differences
between patients and reference population were observed
for frequencies of women with any referral to exercise
therapy, mental healthcare, non-surgical specialties, and
surgical specialties.
When analyses were restricted to women in the first 5 years
of the follow-up period, frequencies of women with at least
one annual face-to-face contact, drug prescription, and referral
in the patient group decreased gradually towards that of the
reference group. Frequencies of women prescribed nervous
system drugs (e.g., analgesics and psycholeptics) and antineo-
plastic/immunomodulating agents (mainly hormone antago-
nists and aromatase inhibitors) remained higher among
patients until the third and the fifth years, respectively
(Table 4). Univariate logistic regression analysis showed that a
higher age at diagnosis was related to a higher face-to-face
contact rate (odds ratio, OR 1.06, 95 % CI 1.04–1.08) and a
higher drug prescription rate (OR 1.07, 95 % CI 1.05–1.09)
during the entire follow-up period (Table 5). This was illus-
trated by more patients in the oldest age group (>65.0 years)
than patients in the younger age groups having >4.0 face-to-
face contacts and >12.3 prescriptions per year. Treatment with
chemotherapy after diagnosis was associated with a lower
face-to-face contact rate (OR 0.56, 95 % CI 0.34–0.93) and
a lower drug prescription rate (OR 0.52 95 % CI 0.31–0.86)
during the follow-up period. Treatment with endocrine thera-
py was associated with a higher drug prescription rate (OR:
1.64, 95 % CI 1.02–2.65) in this period. Multivariate logistic
regression analysis was not performed since only age at diag-
nosis reached a p value ≤0.01.
Discussion
This study explored reasons for primary healthcare use
among women with a history of breast cancer compared
with women without breast cancer and identified patient
characteristics associated with this healthcare use in the
period after completion of primary breast cancer treat-
ment. Over the entire follow-up period (starting 1 year
post-diagnosis), healthcare utilisation rates in the patient
group were significantly higher than those in the reference
group, indicating current involvement of GPs in breast
cancer follow-up care.
More patients than women from the reference population
had face-to-face contacts for reasons related to breast cancer or
were prescribed hormone antagonists and aromatase inhibitors
to treat breast cancer. In The Netherlands, hormone antago-
nists and aromatase inhibitors are initially prescribed by
Table 2 Annual primary healthcare use during the entire follow-up
period (starting 1 year post-diagnosis) among women with a history of
breast cancer (n0336) and women from the reference population (Ref.;
n0983)
Patients Ref.
Face-to-face contacts per year
Median (range)*** 4.0 (0.0–36.5) 3.2 (0.0–70.7)
Any face-to-face contact, n (%)* 325 (96.7) 913 (92.9)
Categories, n (%)
≤1.0 30 (8.9) 151 (15.4)
1.1–3.0 94 (28.0) 323 (32.9)
3.1–6.0 108 (32.1) 284 (28.9)
>6.0 104 (31.0) 225 (22.9)
Drug prescriptions per year
Median (range)*** 12.3 (0.0–191.2) 8.4 (0.0–122.0)
Any drug prescription, n (%) 322 (95.8) 918 (93.4)
Categories, n (%)
≤1.0 27 (8.0) 137 (13.9)
1.1–8.0 101 (30.1) 334 (34.0)
8.1–20.0 103 (30.7) 297 (30.2)
>20.0 105 (31.3) 215 (21.9)
Referrals per year
Median (range)*** 0.4 (0.0–8.1) 0.3 (0.0–6.1)
Any referral, n (%)** 257 (76.5) 671 (68.3)
Categories, n (%)
≤1.0 259 (77.1) 805 (81.9)
1.1–2.0 58 (17.3) 145 (14.8)
>2.0 19 (5.7) 33 (3.4)
Mann–Whitney test or Chi-square test
* p<0.05; ** p<0.01; *** p<0.001
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Table 3 Reasons for primary
healthcare use during the entire
follow-up period (starting 1 year
post-diagnosis) among women
with a history of breast cancer




Subgroups (based on 3-digit
ICPC codes and 3–7-digit
ATC codes) with no significant
differences between patients
and reference population or with
an expected count of less
than five are not shown in this
table
aIncluding physical therapy,
Cesar therapy, and Mensendieck
therapy
















Any face-to-face contact by ICPC chapter/3-digit ICPC code, n (%)
General and unspecified (A) 180 (53.6) 501 (51.0)
Blood, blood-forming organs, and immune mechanism (B) 43 (12.8) 130 (13.2)
Digestive (D) 142 (42.3) 458 (46.6)
Eye (F) 93 (27.7) 309 (31.4)
Ear (H)* 98 (29.2) 356 (36.2)
Excessive ear wax (H81)* 53 (15.8) 207 (21.1)
Cardiovascular (K) 177 (52.7) 564 (57.4)
Musculoskeletal (L) 249 (74.1) 708 (72.0)
Neurological (N) 101 (30.1) 331 (33.7)
Psychological (P) 117 (34.8) 297 (30.2)
Respiratory (R) 202 (60.1) 574 (58.4)
Skin (S) 209 (62.2) 625 (63.6)
Endocrine, metabolic, and nutritional (T) 80 (23.8) 245 (24.9)
Urological (U) 95 (28.3) 281 (28.6)
Pregnancy, childbearing, and family planning (W) 11 (3.3) 37 (3.8)
Female genital (X)** 162 (48.2) 381 (38.8)
Breast cancer (X76)*** 66 (19.6) 0 (0.0)
Social problems (Z) 63 (18.8) 204 (20.8)
Any drug prescription by ATC chapter/3–7-digit ATC code, n (%)
Alimentary tract and metabolism (A) 189 (56.3) 508 (51.7)
Blood and blood-forming organs (B) 102 (30.4) 305 (31.0)
Cardiovascular system (C) 185 (55.1) 541 (55.0)
Dermatologicals (D) 179 (53.3) 503 (51.2)
Genitourinary system and sex hormones (G)** 56 (16.7) 243 (24.7)
Sex hormones and modulators of the genital system (G03)*** 22 (6.5) 191 (19.4)
Hormonal contraceptives for systemic use (G03A)*** 3 (0.9) 81 (8.2)
Progestogens and estrogens, fixed combinations (G03AA)*** 3 (0.9) 71 (7.2)
Levonorgestrel and estrogen (G03AA07)*** 3 (0.9) 55 (5.6)
Progestogens (G03D)* 3 (0.9) 35 (3.6)
Progestogens and estrogens in combination (G03F)* 1 (0.3) 19 (1.9)
Systemic hormonal preparations, excl. sex hormones and insulins (H) 88 (26.2) 266 (27.1)
Anti-infectives for systemic use (J) 255 (75.9) 696 (70.8)
Antineoplastic and immunomodulating agents (L)*** 86 (25.6) 16 (1.6)
Endocrine therapy (L02)*** 80 (23.8) 2 (0.2)
Hormone antagonists and related agents (L02B)*** 78 (23.2) 1 (0.1)
Anti-estrogens (L02BA)*** 66 (19.6) 1 (0.1)
Tamoxifen (L02BA01)*** 66 (19.6) 1 (0.1)
Aromatase inhibitors (L02BG)*** 28 (8.3) 0 (0.0)
Musculoskeletal system (M) 184 (54.8) 560 (57.0)
Nervous system (N) 220 (65.5) 595 (60.5)
Respiratory system (R) 160 (47.6) 466 (47.4)
Sensory organs (S)** 88 (26.2) 333 (33.9)
Ophthalmologicals (S01)** 67 (19.9) 279 (28.4)
Anti-infectives (S01A)** 32 (9.5) 169 (17.2)
Antibiotics (S01AA)** 32 (9.5) 167 (17.0)
Fusidic acid (S01AA13)** 18 (5.4) 111 (11.3)
Any referral by specialty, n (%)
Exercise therapya 98 (29.2) 294 (29.9)
Mental healthcareb 23 (6.8) 78 (7.9)
Non-surgical specialtiesc 151 (44.9) 424 (43.1)
Surgical specialtiesd 162 (48.2) 458 (46.6)
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oncologists. Although not mentioned in the Dutch breast
cancer guidelines [24, 25], patients may receive these drugs
on repeat prescription in general practice [26], on request of
the oncologist. This repeat prescription usually occurs without
direct doctor–patient contact [27]. Fewer patients than women
from the reference population were prescribed non-breast
cancer-related sex hormones. This result is in line with the
guideline from the Dutch College of General Practitioners
[28] that strongly advises against treating menopausal symp-
toms with hormones in women with a history of breast cancer.
Analyses restricted to women in the first 5 years of the
follow-up period showed that healthcare use in the patient
group decreased gradually towards that of the reference
group, while frequencies of women prescribed nervous
system drugs (e.g., analgesics and psycholeptics) and antineo-
plastic/immunomodulating agents (mainly hormone antago-
nists and aromatase inhibitors) remained higher among
patients until the third and the fifth years, respectively. Other
studies have reported on the long-term psychological impact
of breast cancer and its treatment [29, 30]. Recently, an
increased prescription of psychotropic medication was found
in breast cancer patients on endocrine therapy [23]. In our
study, no significant differences between patients and refer-
ence population were observed for frequencies of women with
any referral to mental healthcare. Anxiety and depression are
usually managed in primary care by GPs and their teams,
which may include psychologists and counsellors [31].
The main predictor of higher rates of face-to-face con-
tacts and drug prescriptions throughout the entire follow-up
period was a higher age at diagnosis. This might indicate the
presence of co-morbid conditions in older women with a
history of breast cancer. As co-morbidity is associated with
decreased overall survival and increased mortality among
older breast cancer patients [32], there is a need to integrate
cancer surveillance, preventive care, and general medical
care for those co-morbid conditions [2, 33]. Comprehen-
siveness of care is one of the important potential benefits of
primary care-based follow-up [34]. When follow-up is
transferred to the primary care setting, new responsibilities
of GPs might be incorporated into existing primary health-
care delivery to patients with a history of breast cancer. In
that case, however, GPs have to move from a reactive to a
proactive role in follow-up care [2]. Training of GPs might
be necessary to ensure that they have adequate knowledge
and feel confident to provide this care [14, 35]. Moreover,
they require additional practice supports in order to effec-
tively manage their new responsibilities that come with
caring for breast cancer survivors.
A major strength of the present study is the use of a
primary care database to analyse healthcare utilisation rates
among women with a history of breast cancer and women
without breast cancer from the same population [20]. As the
presentation of health problems was recorded by GPs, our
Table 4 Timing of primary healthcare use during the first 5 years of
the follow-up period among women with a history of breast cancer
(n0336) and women from the reference population (Ref.; n0983)
Any, n (%)
Patients Ref.
Follow-up year 1 n0200 n0584
Face-to-face contact 176 (88.0)** 454 (77.7)
Psychological (P) 33 (16.5)** 50 (8.6)
Female genital (X) 56 (28.0)** 108 (18.5)
Drug prescriptions 175 (87.5) 477 (81.7)
Antineoplastic/immunomodulating
agents (L)
68 (34.0)*** 2 (0.3)
Nervous system (N) 94 (47.0)** 205 (35.1)
Referrals 72 (36.0)* 162 (27.7)
Follow-up year 2 n0174 n0536
Face-to-face contacts 148 (85.1) 425 (79.3)
Psychological (P) 23 (13.2) 48 (9.0)
Female genital (X) 42 (24.1)** 76 (14.2)
Drug prescriptions 156 (89.7)* 441 (82.3)
Antineoplastic/immunomodulating
agents (L)
57 (32.8)*** 2 (0.4)
Nervous system (N) 82 (47.1)** 193 (36.0)
Referrals 58 (33.3) 172 (32.1)
Follow-up year 3 n0160 n0512
Face-to-face contacts 131 (81.9) 407 (79.5)
Psychological (P) 21 (13.1) 52 (10.2)
Female genital (X) 37 23.1* 74 14.5
Drug prescriptions 135 (84.4) 432 (84.4)
Antineoplastic/immunomodulating
agents (L)
42 (26.3)*** 2 (0.4)
Nervous system (N) 76 (47.5)** 181 (35.4)
Referrals 62 (38.8) 167 (32.6)
Follow-up year 4 n0138 n0485
Face-to-face contacts 106 (76.6) 379 (78.1)
Psychological (P) 17 (12.3) 45 (9.3)
Female genital (X) 25 18.1 81 16.7
Drug prescriptions 114 (82.6) 410 (84.5)
Antineoplastic/immunomodulating
agents (L)
34 (24.6)*** 3 (0.6)
Nervous system (N) 52 (37.7) 187 (38.6)
Referrals 43 (31.2) 155 (32.0)
Follow-up year 5 n0133 n0480
Face-to-face contacts 97 (72.9) 371 (77.3)
Psychological (P) 16 (12.0) 56 (11.7)
Female genital (X) 24 (18.0) 54 (11.2)
Drug prescriptions 104 (78.2) 386 (80.4)
Antineoplastic/immunomodulating
agents (L)
23 (17.3)*** 6 (1.3)
Nervous system (N) 51 (38.3) 181 (37.7)
Referrals 18 (33.3) 60 (26.8)
Chi-square test
* p<0.05; ** p<0.01; *** p<0.001
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study is much less prone to recall or non-response bias than
surveys with self-reported data on healthcare use [36]. Al-
though some concerns have been raised about the validity of
the data in primary care databases [37], the likelihood that
the breast cancer code was valid in the patient records
increased considerably by going back to the participating
general practices for confirmation of the breast cancer diag-
nosis. A matter of concern might be the completeness or
Table 5 Rates of face-to-face
contacts and drug prescriptions
during the entire follow-up peri-
od (starting 1 year post-
diagnosis) by characteristics of
patients with a history of breast
cancer (n0336). Univariate
analysis, odds ratios (OR), and
95 % confidence intervals (95 %
CI) estimated with logistic
regression analysis
aIncluding patients treated with
lumpectomy, with and
without radiation therapy
bIncluding patients treated with
lumpectomy followed by




≤ median > median OR (CI)
Outcome: annual face-to-face contact rate ≤4.0 (n0168) >4.0 (n0168)
Age at diagnosis (years) 1.06 (1.04–1.08)***
Categories, n (%)
≤50.0 79 (47.0) 37 (22.0)
50.1–65.0 60 (35.7) 60 (35.7)
>65.0 29 (17.3) 71 (42.3)
T stage, n (%)
Tis/T1 84 (60.0) 76 (55.5) 1
T2/T3/T4 56 (40.0) 61 (44.5) 1.20 (0.75–1.94)
N stage, n (%)
N0 101 (64.7) 97 (65.5) 1
N+ 55 (35.3) 51 (34.5) 0.97 (0.60–1.55)
Surgery, n (%)
Lumpectomya 69 (41.8) 52 (31.5) 1
Mastectomyb 96 (58.2) 113 (68.5) 1.58 (0.99–2.50)
Chemotherapy, n (%)
No 106 (67.1) 124 (78.5) 1
Yes 52 (32.9) 34 (21.5) 0.56 (0.34–0.93)*
Endocrine therapy, n (%)
No 112 (71.3) 101 (64.3) 1
Yes 45 (28.7) 56 (35.7) 1.38 (0.86–2.22)
Outcome: annual drug prescription rate ≤12.3 (n0168) >12.3 (n0168)
Age at diagnosis (years) 1.07 (1.05–1.09)***
Categories, n (%)
≤50.0 78 (46.4) 38 (22.6)
50.1–65.0 70 (41.7) 50 (29.8)
>65.0 20 (11.9) 80 (47.6)
T stage, n (%)
Tis/T1 85 (60.3) 75 (55.1) 1
T2/T3/T4 56 (39.7) 61 (44.9) 1.23 (0.77–1.99)
N stage, n (%)
N0 100 (63.3) 98 (67.1) 1
N+ 58 (36.7) 48 (32.9) 0.84 (0.53–1.36)
Surgery, n (%)
Lumpectomya 69 (43.4) 52 (35.1) 1
Mastectomyb 90 (56.6) 96 (64.9) 1.42 (0.89–2.24)
Chemotherapy, n (%)
No 107 (66.5) 123 (79.4) 1
Yes 54 (33.5) 32 (20.6) 0.52 (0.31–0.86)*
Endocrine therapy, n (%)
No 117 (73.1) 96 (62.3) 1
Yes 43 (26.9) 58 (37.7) 1.64 (1.02–2.65)*
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sensitivity of the data in primary care databases [36, 37]. In
the present study, matching was performed on GP to ensure
that inaccuracies in recording and prescription were evenly
distributed among patients and women from the reference
population. The possibility of patients diagnosed with breast
cancer without the breast cancer code in their record [38]
cannot be ruled out, as the used data pertain to those con-
ditions that were brought to the attention of the GPs and
were recorded with ICPC codes. Furthermore, we were not
able to compare menopausal status [39] between the patient
group and reference group because our primary care data-
base does not include information on this status. Finally,
these data apply to a population in the northern part of The
Netherlands that might be influenced by local healthcare
structures [40].
Dutch GPs have not traditionally played a formal role in
breast cancer follow-up care. However, our study showed
their informal role in care for patients with a history of
breast cancer. This study provides needed data to re-design
the follow-up care for women with breast cancer. When
follow-up is transferred to the primary care setting, new
responsibilities of GPs might be incorporated into existing
primary healthcare delivery.
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